Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ Quantitative Report
$104.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioSpecifics Technologies Corp announces positive data from Phase 2a study of CCH for treatment of Cellulite


Thursday, 21 Aug 2014 05:36pm EDT 

BioSpecifics Technologies Corp:Says positive, statistically results from randomized, double-blind Phase 2a study of CCH for potential treatment of cellulite, or edematous fibrosclerotic panniculopathy.Results showed that all three doses of CCH used in the study, including low, medium and high dose, demonstrated improvement in appearance of cellulite as measured by trial endpoints of physician and patient-assessed improvements.CCH was well-tolerated by all dose groups with most adverse events being mild to moderate and primarily limited to local injection area. 

Company Quote

38.02
 --
24 Dec 2014